Dr Michael Perry is senior vice president and chief scientific officer of Global Business Development and Licensing for Novartis AG. From 2014 to 2016, Dr Perry was chief scientific officer of Novartis’ Cell and Gene Therapy Unit, and from 2012 to 2014 was vice president and global head of Stem Cell Therapy for Novartis Pharmaceuticals Corp, a US affiliate of Switzerland-based Novartis AG. Dr Perry, based in the United States, was also global head of R&D at Baxter Healthcare, president and chief executive of Cell & Gene Therapy at Novartis affiliates Systemix and Genetic Therapy, vice president of regulatory affairs at Sandoz Pharmaceuticals, director of regulatory affairs at Schering-Plough Corporation, chair and chief executive of several early stage biotech companies. He also previously served as a Venture Partner with Bay City Capital, based in San Francisco California.
